Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose is to test whether dose densified chemoimmunotherapy followed by central nervous
system (CNS) prophylaxis for young high risk diffuse large B-cell lymphoma (DLBCL) patients
is feasible and could improve time to treatment failure and reduce the risk of CNS relapses.
Six courses of rituximab-cyclophosphamide-doxorubicin-etoposide-vincristine-prednison
(R-CHOEP) given in two weeks intervals with the support of G-CSF is followed by one course of
high dose methotrexate (HD-MTX) and high dose cytarabine (HD-Ara-C). The results will be
compared to a historical Nordic study.